Related Experiment Video
Updated: Oct 30, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve
Paula Pellenz Tomasini1,2, Temenouga Nikolova Guecheva3, Natalia Motta Leguisamo1
1Laboratory of Genetic Toxicology, Federal University of Health Sciences of Porto Alegre, Avenida Sarmento Leite, 245, Porto Alegre 90050-170, Brazil.
Abstract:
Despite the ample improvements of CRC molecular landscape, the therapeutic options still rely on conventional chemotherapy-based regimens for early disease, and few targeted agents are recommended for clinical use in the metastatic setting. Moreover, the impact of cytotoxic, targeted agents, and immunotherapy combinations in the metastatic scenario is not fully satisfactory, especially the outcomes for patients who develop resistance to these treatments need to be improved. Here, we examine the opportunity to consider therapeutic agents targeting DNA repair and DNA replication stress response as strategies to exploit genetic or functional defects in the DNA damage response (DDR) pathways through synthetic lethal mechanisms, still not explored in CRC. These include the multiple actors involved in the repair of DNA double-strand breaks (DSBs) through homologous recombination (HR), classical non-homologous end joining (NHEJ), and microhomology-mediated end-joining (MMEJ), inhibitors of the base excision repair (BER) protein poly (ADP-ribose) polymerase (PARP), as well as inhibitors of the DNA damage kinases ataxia-telangiectasia and Rad3 related (ATR), CHK1, WEE1, and ataxia-telangiectasia mutated (ATM). We also review the biomarkers that guide the use of these agents, and current clinical trials with targeted DDR therapies.
Insights
Targeting DNA repair and replication stress response pathways offers a novel synthetic lethal strategy for colorectal cancer (CRC). This approach exploits DNA damage response (DDR) defects to improve treatment outcomes for metastatic CRC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Current colorectal cancer (CRC) treatments, especially for metastatic disease, have limited efficacy and face challenges with treatment resistance.
- Conventional chemotherapy and existing targeted agents/immunotherapy combinations show unsatisfactory outcomes in the metastatic setting.
Purpose of the Study:
- To explore the potential of targeting DNA repair and replication stress response pathways in CRC.
- To investigate synthetic lethal strategies that exploit DNA damage response (DDR) pathway defects in colorectal cancer.
Main Methods:
- Reviewing therapeutic agents targeting DNA double-strand break (DSB) repair pathways (homologous recombination, NHEJ, MMEJ).
- Examining inhibitors of base excision repair (BER) protein poly (ADP-ribose) polymerase (PARP).
- Analyzing inhibitors of DNA damage kinases like ATR, CHK1, WEE1, and ATM.
Main Results:
- The study identifies multiple DDR pathways and their inhibitors as potential therapeutic targets in CRC.
- Exploiting synthetic lethality through DDR inhibition is a promising, yet underexplored, strategy for CRC.
Conclusions:
- Targeting DNA repair and replication stress response mechanisms presents a novel therapeutic avenue for colorectal cancer.
- Further research into DDR-targeting agents and associated biomarkers is crucial for improving outcomes in metastatic CRC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
DNA Damage can Stall the Cell Cycle
Fixing Double-strand Breaks
Fixing Double-strand Breaks
Homologous Recombination
Overview of DNA Repair
Chemically...

